MedTrace Logo

Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

NCT05288400 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-06-05

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and the safety of a fixed-dose combination in capsule of Amlodipine 5mg/ Bisoprolol fumarate 5mg/ Perindopril arginine 5mg, and free monotherapy at the same dose in patients with uncontrolled essential hypertension.

Conditions

  • Essential Hypertension

Interventions

COMBINATION_PRODUCT

Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg

1 capsule/day Oral administration

DRUG

Norvasc 5mg tablet

Norvasc (amlodipine) 5mg, 1 tablet/day

DRUG

Concor 5mg tablet

Concor (bisoprolol fumarate) 5mg, 1 tablet/day

DRUG

Coversyl 5mg tablet

Coversyl (perindopril arginine) 5mg, 1 tablet/day

Sponsors & Collaborators

Principal Investigators

  • Alexandra Konradi · Almazov National Medical Research Centre - Department of Hypertension, Saint Petersburg, Russia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2018-12-18
Completion
2018-12-18

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288400 on ClinicalTrials.gov